synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-09 and is reviewed periodically as new material appears.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
=== Cardiovascular disease === Cardiovascular disease can present itself in many different forms, from cardiomyopathy to peripheral arterial disease, and heart disease remains a key threat to human health. While there are means of therapy to both prevent and cure cardiovascular diseases, many drugs are unavailable for clinical use due to severe side effects in addition to high toxicity levels. However, in the past decade, sv-LAAOs have shown promise in affecting platelet aggregation. It has been proposed that hydrogen peroxide is considered to play a significant role regarding the enzymes ability to both cause and prevent this platelet aggregation. With this knowledge, it appears that sv-LAAOs could be evaluated as a potential cardiovascular disease therapeutic because of their biological potency.
There are as many mass-balance equations as there are reagents, A, B..., so if the equilibrium constant values are known, there are n mass-balance equations in n unknowns, [A], [B]..., the so-called free reagent concentrations. Solution of these equations gives all the information needed to calculate the concentrations of all the species. Thus, the importance of equilibrium constants lies in the fact that, once their values have been determined by experiment, they can be used to calculate the concentrations, known as the speciation, of mixtures that contain the relevant species.
== Further reading == Robinson, David A. (2008), "Field Estimation of Soil Water Content: A Practical Guide to Methods, Instrumentation and Sensor Technology" (PDF), Soil Science Society of America Journal, 73 (4), Vienna, Austria: International Atomic Energy Agency: 131, Bibcode:2009SSASJ..73.1437R, doi:10.2136/sssaj2008.0016br, ISSN 1018-5518, IAEA-TCS-30 Wessel-Bothe, Weihermüller (2020): Field Measurement Methods in Soil Science. New practical guide to soil measurements explains the principles of operation of different moisture sensor types (independent of manufacturer), their accuracy, fields of application and how such sensors are installed, as well as subtleties of the data so obtained. Also deals with other crop-related soil parameters.
c-MET may interact with FoxM1, a molecule important in the cell cycle, as FOXM1 levels decrease when c-MET is not present. Additionally, c-MET may interact with p27 as the protein levels increase when c-MET is not present. Another hypothesis says that c-MET may control β-cell apoptosis because a lack of c-MET causes increased cell death, but the signaling mechanisms have not been elucidated. Although the mechanism of HGF/c-MET control of gestational diabetes is not yet well understood, there is a strong correlation between the signaling pathway and the inability to produce an adequate amount of insulin during pregnancy, and thus it may be the target for future diabetic therapies. Because glucose travels across the placenta (through diffusion facilitated by GLUT1 carrier), which is located in the syncytiotrophoblast on both the microvilli and basal membranes, these membranes may be the rate-limiting step in placental glucose transport. There is a two- to three-fold increase in the expression of syncytiotrophoblast glucose transporters with advancing gestation. Finally, the role of GLUT3/GLUT4 transport remains speculative. If the untreated gestational diabetes fetus is exposed to consistently higher glucose levels, this leads to increased fetal levels of insulin (insulin itself cannot cross the placenta). The growth-stimulating effects of insulin can lead to excessive growth and a large body (macrosomia).
Sources: en.wikipedia.org
=== Human capital === In order to benefit from the advent of digital agriculture, farmers must develop new skills. As Bronson (2018) notes, "training a rural work-force in Internet technology skills (e.g., coding) is obviously a key part of agricultural "modernization." Integration into the digital economy requires basic literacy (ability to read) and digital literacy (ability to use digital devices to improve welfare). In many instances, benefiting from digital content also requires English literacy or familiarity with another widely spoken language. Digital agriculture developers have designed ways around these barriers, such as ICTs with audio messages and extension videos in local languages. However, more investment in human capital development is needed to ensure all farmers can benefit from digital agriculture. Fostering human capital in the form of innovation also matters for the spread of digital agriculture. Some characterize digital agriculture innovation, a knowledge- and skills-intensive process, as concentrated in "Big Ag" companies and research universities. However, others describe small-scale entrepreneurs as the "heart of the action." In 2018, ag-tech innovation attracted $1.9 billion in venture capital, and the sector has grown significantly in the last 10 years. Although digital agriculture may be concentrated in a few developed countries because of "structure, institutional, and economic barriers," ag-tech startups have experienced significant growth in Africa, the Caribbean and Pacific, Asia, and Latin America as well.
Genetic screens conducted in Drosophila led to the identification of several proteins that play a central role in Notch signaling, including Enhancer of split, Master mind, Delta, Suppressor of Hairless (CSL), and Serrate. At the same time, the Notch gene was successfully sequenced and cloned, providing insights into the molecular architecture of Notch proteins and led to identification of Notch homologs in Caenorhabditis elegans (C. elegans) and eventually in mammals. In the early 1990s Notch was increasingly implicated as the receptor of a previously unknown intercellular signal pathway in which the Notch intercellular domain (NICD) is transported to the nucleus where it acts as a transcription factor to directly regulate target genes. The release of the NICD was found to be as a result of proteolytic cleavage of the transmembrane protein through the actions of the γ-secretase complex catalytic subunit Presenilin. This was a significant interaction as Presenilin is implicated in the development of Alzheimer's disease. This and further research into the mechanism of Notch signaling led to research that would further connect Notch to a wide range of human diseases.
== Biography == Macleod was born in Clunie, near Dunkeld in Perthshire. Soon after he was born, his father Robert Macleod, a minister of the Free Church, was transferred to Aberdeen, where John attended Aberdeen Grammar School and enrolled in the study of medicine at the University of Aberdeen. At the University of Aberdeen, one of MacLeod's principal teachers was the young professor John Alexander MacWilliam. He was awarded his medical degree with honours in 1898 and then spent a year studying biochemistry at the University of Leipzig, Germany, on a travelling scholarship. He became a demonstrator at the London Hospital Medical School, where in 1902 he was appointed lecturer in biochemistry. In the same year, he was awarded a doctorate in public health from Cambridge University. Around that time he published his first research article, a paper on phosphorus content in muscles. In 1903, Macleod became a lecturer in physiology at the Western Reserve University in Cleveland, Ohio, where he remained for 15 years. This was the period when he developed an interest in carbohydrate metabolism that was to last for the rest of his career. In 1910, he delivered a lecture on various forms of experimental diabetes and their significance for diabetes mellitus at the joint meeting of the section on Pharmacology and Therapeutics and the section on Pathology and Physiology of the American Medical Association. In 1916, he was a Professor of Physiology at McGill University in Montreal, Canada.
The 1–508 PIR served in Regional Command-South. Working mostly out of Kandahar province as the theater tactical force, they mentored the Afghan National Security Force (ANSF), conducting combined operations with both ANSF and NATO partners in the Helmand Province. Supporting the division were the 36th Engineer Brigade, and the 43d Area Support Group.
Financial response The primary financial restitution paid by UCC was negotiated in 1989, when the Indian Supreme Court approved a settlement of US$470 million (₹1,055 crore; equivalent to $1.03 billion in 2024). This amount was immediately paid by UCC to the Indian government. The company states that the restitution paid "was $120 million more than plaintiffs' lawyers had told U.S. courts was fair" and that the Indian Supreme Court stated in its opinion that "compensation levels under the settlement were far greater than would normally be payable under Indian law." In the immediate aftermath of the disaster, Union Carbide states on its website that it donated $2 million to the Indian prime minister's immediate disaster relief fund on 11 December 1984. The corporation established the Employees' Bhopal Relief Fund in February 1985, which raised more than $5 million for immediate relief. According to Union Carbide, in August 1987, they made an additional $4.6 million in humanitarian interim relief available. Union Carbide stated that it also undertook several steps to provide continuing aid to the victims of the Bhopal disaster, including the sale of its 50.9% interest in UCIL in April 1992 and establishment of a charitable trust to contribute to the building of a local hospital. The sale was finalised in November 1994. Construction began in October 1995 and the hospital opened in 2001. The company provided a fund of around $90 million from sale of its UCIL stock. In 1991, the trust had amounted to approximately $100 million.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.